主动监测早期前列腺癌活检重分类的风险因素
研究纳入2000-2016年加州大学旧金山分校1031例低危前列腺癌主动监测患者,采用多变量Cox模型分析活检重分类(Gleason分级组≥2)的预测因素。结果显示PSA密度≥0.15、阳性穿刺针百分比和高基因组评分与首次监测活检及1-3年重分类相关,PSA密度≥0.15和PSA动力学与3-5年重分类相关,而PI-RADS 4-5评分与任何时间点重分类无关。
要点
- PSA密度≥0.15和高基因组评分可预测3年内活检重分类。
- PSA动力学和PSA密度≥0.15与5年内重分类持续相关。
- PI-RADS 4-5评分与活检重分类无显著关联。
核心结论
- 高基因组评分、PSA动力学和PSA密度≥0.15与主动监测开始后3年内重分类相关,后两者在诊断后5年仍与重分类相关。
研究设计与样本
- 前瞻性队列研究,纳入2000-2016年加州大学旧金山分校1031例临床低危前列腺癌主动监测患者,采用多变量Cox比例风险回归模型分析。
主要发现
- 首次监测活检及1-3年,活检重分类与PSA密度≥0.15(HR 3.37,95%CI 1.83-6.21)、阳性穿刺针百分比(HR 1.27,95%CI 1.05-1.54)和高基因组评分(HR 2.81,95%CI 1.21-6.52)相关。
- 3-5年,重分类与PSA密度≥0.15(HR 2.36,95%CI 1.56-3.56)和PSA动力学(HR 2.19,95%CI 1.43-3.34)相关。
- PI-RADS 4-5评分在任何时间点均与活检重分类无关。
关键数值与推荐
- 活检重分类定义为后续活检Gleason分级组≥2。
- PSA密度阈值为0.15或更高。
- PI-RADS 4-5评分未显示与重分类的显著关联。
临床怎么用
- 对于低危前列腺癌主动监测患者,可结合PSA密度、PSA动力学和基因组评分评估重分类风险,以个体化调整活检频率。
- PI-RADS 4-5评分不宜单独用于预测活检重分类。
局限性
- 研究为单中心前瞻性队列,结果外推需谨慎。
- 未报告基因组检测的具体类型和阈值。
- 未涉及其他潜在混杂因素如种族、合并症等对结果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Few validated clinical tools currently exist to standardize the frequency of biopsies for men on active surveillance for low risk prostate cancer. We determined predictors of biopsy reclassification at specific time points after enrollment on active surveillance. MATERIALS AND METHODS: We identified men with clinically low risk prostate cancer prospectively enrolled on active surveillance at the University of California, San Francisco between 2000 and 2016. Biopsy reclassification was defined as Gleason Grade Group 2 or greater on subsequent biopsy. Multivariable Cox proportional hazards regression models were used to identify factors associated with risk of biopsy reclassification at first surveillance biopsy and 1 to 3, 3 to 5 and 5 to 10 years after enrollment, adjusting for clinicodemographic factors, PI-RADS® (Prostate Imaging Reporting and Data System) score and genomic testing. RESULTS: A total of 1,031 men were included in the study. On multivariable analysis biopsy reclassification was associated with prostate specific antigen density 0.15 or greater (HR 3.37, 95% CI 1.83-6.21), percentage biopsy cores positive (HR 1.27, 95% CI 1.05-1.54) and high genomic score (HR 2.81, 95% CI 1.21-6.52) at first surveillance biopsy and also at 1 to 3 years, after adjustment. Prostate specific antigen density 0.15 or greater (HR 2.36, 95% CI 1.56-3.56) and prostate specific antigen kinetics (HR 2.19, 95% CI 1.43-3.34) were associated with reclassification at 3 to 5 years. A PI-RADS 4-5 score was not associated with biopsy reclassification at any time point. CONCLUSIONS: High genomic score, prostate specific antigen kinetics and prostate specific antigen density 0.15 or greater were associated with reclassification within 3 years of commencing active surveillance, and prostate specific antigen kinetics and prostate specific antigen density 0.15 or greater remained associated with reclassification at 5 years after diagnosis.
引用
- Lonergan PE, Washington SL, Cowan JE, et al. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2020. PMID: 32519915. doi:10.1097/JU.0000000000001186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。